Drugs / TM123
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04230265 | Jan 2020 → Apr 2025 | acute myeloid leukemia | AvenCell Europe GmbH | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-02-03 | AvenCell Europe GmbH | Results GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients with Relapsed/Refractory AML (rrAML) to be Presented at Virtual 3rd EHA-EBMT European CAR T-Cell Meeting avencell.com ↗
UniCAR-T-CD123 has demonstrated a favorable safety and efficacy profile in rrAML. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-02-03 | AvenCell Europe GmbH | GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients with Relapsed/Refractory AML (rrAML) to be Presented at Virtual 3rd EHA-EBMT European CAR T-Cell Meeting avencell.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TM123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04230265 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant antibody derivative (TM123)” NCT04230265 ↗ |
| Route | Intravenous | “Intravenous Infusion for 20 days” NCT04230265 ↗ |